Analyst picks & changes

Amgen Inc.

(AMGN)

Immunex Corp.

(IMNX)

Analysts were virtually unanimous in concluding that a positive FDA advisory panel review of IMNX's request for a label expansion for

Leukine

GM-CSF will have little or no impact on sales of the colony stimulating factor, and hence no impact on the market dominance of AMGN's

Neupogen

G-CSF (see page B4). The company has requested labels for both chemotherapy-induced neutropenia (CIN) and

Read the full 707 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE